Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.
暂无分享，去创建一个
D. Planchard | J. Soria | C. Lindsay | B. Besse | F. Commo | N. Auger | J. Remon | F. Farace | F. Billiot | I. Borget | E. Pailler | M. Oulhen | Kirsty Ross | M. Ngo Camus